Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745904 | 0.87 | NR1H2 (0.43) | MAPTNR1H2NR1H3SIGMAR1RECQL | |
| SCHEMBL16025064 | 0.86 | MAPT (0.54) | MAPTNR1H2NR1H3 | |
| SCHEMBL22399609 | 0.84 | GRM6 (0.43) | MAPTNR1H2NR1H3CHRM2CHRM4 | |
| SCHEMBL22399617 | 0.84 | GRM6 (0.43) | MAPTNR1H2NR1H3CHRM2CHRM4 | |
| SCHEMBL5369260 | 0.81 | CHRM2 (0.41) | MAPTNR1H2NR1H3CHRM2CHRM4 | |
| SCHEMBL31127193 | 0.81 | MMP2 (0.46) | MAPT | |
| SCHEMBL5746137 | 0.78 | FUCA1 (0.47) | SIGMAR1RECQLSMN1; SMN2HRH3 | |
| SCHEMBL20799630 | 0.76 | RECQL (0.45) | RECQLSMN1; SMN2 | |
| SCHEMBL30339801 | 0.75 | OPRD1 (0.44) | RECQLSMN1; SMN2 | |
| SCHEMBL5744290 | 0.74 | SLC6A4 (0.46) | MAPTNR1H2NR1H3SIGMAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | MAPT 4302/4885NR1H2 3133/4885NR1H3 3196/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | MAPT 4271/4885NR1H2 1079/4885NR1H3 1596/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | MAPT 4271/4885NR1H2 1079/4885NR1H3 1596/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | MAPT 4271/4885NR1H2 1079/4885NR1H3 1596/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | MAPT 4343/4885NR1H2 721/4885NR1H3 992/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | MAPT 4271/4885NR1H2 1079/4885NR1H3 1596/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | MAPT 4302/4885NR1H2 3133/4885NR1H3 3196/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | MAPT 4230/4885NR1H2 864/4885NR1H3 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.